EQRx readies a lower-cost alternative to pricey cancer
immunotherapies
|
|
The biotech and its partner CStone disclosed Phase 3 results in lung cancer that support approval plans for a drug similar to treatments like Merck's Keytruda, but would be priced at a fraction of the cost.
No comments:
Post a Comment